サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794002

人工多能性幹細胞（iPSC）由来オルガノイドの世界市場

Induced Pluripotent Stem Cell (iPSC) Derived Organoids

出版日
ページ情報
英文 231 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
人工多能性幹細胞（iPSC）由来オルガノイドの世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 231 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

人工多能性幹細胞（iPSC）由来オルガノイドの世界市場は2030年までに17億米ドルに達する見込み

2024年に5億5,970万米ドルと推定される人工多能性幹細胞（iPSC）由来オルガノイドの世界市場は、分析期間2024-2030年にCAGR 19.8%で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである脳オルガノイドは、CAGR 21.7%を記録し、分析期間終了時には5億4,500万米ドルに達する見込みです。心臓オルガノイド分野の成長率は、分析期間でCAGR 21.2％と推定されます。

米国市場は1億4,710万米ドルと推定、中国はCAGR18.6％で成長すると予測

米国の人工多能性幹細胞（iPSC）由来オルガノイド市場は、2024年に1億4,710万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2億5,270万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.5％と17.0％と予測されています。欧州では、ドイツがCAGR約14.3％で成長すると予測されています。

世界の人工多能性幹細胞（iPSC）由来オルガノイド市場- 主要動向と促進要因のまとめ

なぜiPS細胞由来オルガノイドが生物医学イノベーションの中心なのか？

人工多能性幹細胞（iPSC）由来オルガノイドは、再生医療、疾患モデリング、創薬において最も革新的な開発の一つとして登場しました。再プログラムされた成体細胞から開発されたこれらの3次元細胞構造は、実際のヒト臓器の構造と機能をミニチュアスケールで模倣しています。臓器特異的なプロセスを再現するその能力は、複雑な生物学的機能を制御された実験室環境で研究する上で非常に貴重です。従来の細胞株や動物モデルとは異なり、iPSC由来のオルガノイドはヒト細胞から作製されるため、疾患の進行や治療反応を評価する際に、より高い生理学的妥当性を提供します。これにより、個別化医療における新たな可能性が開かれ、研究者は個々の患者の臓器を試験管内でモデル化し、薬剤の有効性と安全性を試験できるようになりました。オルガノイドは、脳、肝臓、腎臓、腸、肺など、さまざまなヒトのシステムを調べるために使用されており、科学者はアルツハイマー病、嚢胞性線維症、肝線維症、さまざまながんなどの病気を調べることができます。患者特異的モデルを作成する能力は、これまでヒト組織へのアクセスが限られていたために研究の進展が妨げられてきた希少疾患研究にも変化をもたらしています。プレシジョン・ヘルスケアに対する世界の関心が高まるにつれ、iPS細胞由来のオルガノイドは、実験室での研究と臨床応用のギャップを埋める上でますます重要な役割を果たすようになっており、動物実験に代わる、より正確で倫理的かつスケーラブルな選択肢を提供しています。

技術の進歩は、オルガノイド・モデルの有用性と拡張性をどのように高めているのか？

バイオテクノロジー、組織工学、幹細胞研究の急速な進歩は、iPSC由来のオルガノイドの開発と応用を大きく前進させています。iPSCを再プログラム化し分化させるための洗練されたプロトコールは、現在では、より複雑な構造と機能的成熟度を持ち、in vivoのものと酷似したオルガノイドを産生します。3Dバイオプリンティングとマイクロ流体プラットフォームにおける技術革新は、研究者がオルガノイド形成を精密かつ再現性よく操作することをさらに可能にしています。これらの技術により、血管構造、機械的刺激、細胞外マトリックスの統合が可能になり、よりリアルな挙動と応答性がサポートされます。さらに、培養プロセスを合理化し、スループットを向上させ、バッチ間のばらつきを低減するために、自動化やロボット操作システムが導入されています。このような拡張性は、前臨床薬物スクリーニングや毒性学研究に大量のオルガノイドモデルを求める製薬企業にとって不可欠です。ハイコンテンツイメージングやシングルセルシーケンス技術との統合は、研究者が細胞レベルや分子レベルでオルガノイドの反応を分析できるようにし、さらなる深みを増しています。CRISPR-Cas9のような遺伝子編集ツールの開発も、オルガノイドの発生前にiPS細胞に変異を導入したり修正したりするのに利用されており、前例のない特異性で遺伝性疾患の研究を可能にしています。このように現在進行中の技術革新は、オルガノイドの忠実性と機能性を向上させるだけでなく、ますます多くの科学的・臨床的領域でその利用を拡大しています。

どのような市場や研究ニーズがiPSC由来オルガノイドの普及を促進しているのか？

より正確で、ヒトに関連した生物学的モデルに対する需要は、製薬、学術、臨床研究の各分野でiPSC由来オルガノイドの採用を推進する1次調査の1つです。従来の二次元培養や動物モデルでは、ヒト疾患の複雑性を捉えきれないことが多く、医薬品開発における高い離脱率やトランスレーショナルな成果の限定につながっています。オルガノイドは、ヒトの生理をより忠実に反映する系を提供することにより、薬物の毒性、代謝、治療効果の予測精度を向上させ、この課題に対する解決策を提供します。これは腫瘍学において特に重要であり、腫瘍由来のオルガノイドは化合物のスクリーニングや治療戦略の個別化に用いられています。同様に、感染症研究者は、COVID-19やノロウイルスなどの疾患における病原体と宿主の相互作用を研究するために、肺や腸のオルガノイドに注目しています。倫理的な懸念や動物の使用を減らす規制上の圧力によって、代替の試験モデルを求める動きが強まっていることも、オルガノイド・プラットフォームへの依存を高めています。再生医療の領域では、iPSC由来のオルガノイドは臓器の修復や移植に有望な経路を提供し、実験的アプローチでは肝疾患、網膜変性症、神経疾患の治療の可能性が示されています。バイオテクノロジー企業、大学、ヘルスケア機関の協力により、資金調達と技術革新の両方が加速しており、より幅広い研究者がオルガノイドを利用しやすくなっています。このような広範な応用は、生命科学における信頼性が高く、再現可能で、カスタマイズ可能なモデルに対する緊急かつ増大するニーズを反映しています。

iPS細胞由来オルガノイド市場の世界的拡大を後押ししている要因は何か？

iPSC由来オルガノイドの世界市場が急速に拡大しているのは、科学的、商業的、政策的な要因が重なり合い、生物医学研究と治療法開拓の風景が変わりつつあるためです。主な要因は、個別化医療と精密診断に対する需要の急増であり、これらはいずれも治療計画や薬剤試験のために患者特異的モデルに大きく依存しています。慢性疾患や複雑な疾患の増加により、疾患のメカニズムを研究し、治療戦略を評価するためのより良いツールの必要性が高まっています。その結果、バイオテクノロジー企業や製薬大手は、早期の薬剤スクリーニングを改善し、後期の臨床試験の失敗を減らすために、オルガノイド技術に多額の投資を行っています。幹細胞調査に対する公的・民間資金も増加傾向にあり、政府機関や研究財団がiPS細胞やオルガノイドを活用してイノベーションを加速する取り組みを支援しています。オルガノイド・プラットフォームを取り巻く知的財産はより強固なものとなりつつあり、商業ベンチャーがオルガノイドの生産、維持、分析のための独自のシステムを開発することを後押ししています。さらに、専用のオルガノイド・バイオバンクと標準化されたプロトコルの出現は、再現性と拡張性に関する以前の課題の克服に役立っています。学術機関は、生命科学カリキュラムにオルガノイド研究を組み入れ、この技術を採用し拡大する次世代の科学者を育成しています。世界の共同研究、オープンアクセス出版物、国境を越えた知識交換は、アクセシビリティとイノベーションをさらに高めています。これらの力が相まって、iPSC由来オルガノイド市場の成長を支えているだけでなく、将来の生物医学研究エコシステムの要として位置づけられています。

セグメント

タイプ（脳オルガノイド、心臓オルガノイド、肺オルガノイド、肝臓オルガノイド、腎臓オルガノイド、その他のオルガノイドタイプ）、用途（創薬・研究開発用途、疾患モデル用途、再生医療用途）、最終用途（製薬・バイオテクノロジー企業最終用途、学術・研究機関最終用途、受託研究機関最終用途）

調査対象企業の例

  • Axol Bioscience Ltd.
  • BICO Group AB
  • BioIVT
  • BioSpan Technologies, Inc.
  • BrainXell, Inc.
  • Censo Biotechnologies Ltd.
  • Cellular Dynamics International
  • DefiniGEN Ltd
  • Hubrecht Organoid Technology
  • I Peace, Inc.
  • InSphero AG
  • Kirkstall Ltd
  • MIMETAS B.V.
  • Molecular Devices, LLC
  • Ncardia AG
  • Novasenta Inc.
  • Organovo Holdings Inc.
  • REPROCELL Inc.
  • STEMCELL Technologies Inc.
  • Xilis, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37166

Global Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market to Reach US$1.7 Billion by 2030

The global market for Induced Pluripotent Stem Cell (iPSC) Derived Organoids estimated at US$559.7 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 19.8% over the analysis period 2024-2030. Brain Organoids, one of the segments analyzed in the report, is expected to record a 21.7% CAGR and reach US$545.0 Million by the end of the analysis period. Growth in the Heart Organoids segment is estimated at 21.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$147.1 Million While China is Forecast to Grow at 18.6% CAGR

The Induced Pluripotent Stem Cell (iPSC) Derived Organoids market in the U.S. is estimated at US$147.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$252.7 Million by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.5% and 17.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market - Key Trends & Drivers Summarized

Why Are iPSC-Derived Organoids at the Center of Biomedical Innovation?

Induced pluripotent stem cell (iPSC) derived organoids have emerged as one of the most transformative developments in regenerative medicine, disease modeling, and drug discovery. These three-dimensional cellular structures, developed from reprogrammed adult cells, mimic the architecture and function of real human organs on a miniature scale. Their ability to replicate organ-specific processes makes them invaluable for studying complex biological functions in a controlled laboratory setting. Unlike traditional cell lines or animal models, iPSC-derived organoids are generated from human cells, offering higher physiological relevance when assessing disease progression or therapeutic response. This has opened new possibilities in personalized medicine, where researchers can now model individual patients’ organs in vitro to test drug efficacy and safety. Organoids are being used to explore a wide range of human systems, including brain, liver, kidney, gut, and lung, enabling scientists to investigate diseases such as Alzheimer’s, cystic fibrosis, liver fibrosis, and various cancers. The ability to generate patient-specific models is also transforming rare disease research, where limited access to human tissue has historically hindered progress. As global interest in precision healthcare grows, iPSC-derived organoids are playing an increasingly critical role in bridging the gap between laboratory research and clinical application, offering a more accurate, ethical, and scalable alternative to animal testing.

How Are Technological Advancements Enhancing the Utility and Scalability of Organoid Models?

Rapid progress in biotechnology, tissue engineering, and stem cell research is significantly advancing the development and application of iPSC-derived organoids. Sophisticated protocols for reprogramming and differentiating iPSCs are now producing organoids with greater structural complexity and functional maturity, closely resembling their in vivo counterparts. Innovations in 3D bioprinting and microfluidic platforms are further enabling researchers to manipulate organoid formation with precision and reproducibility. These technologies allow for the integration of vascular structures, mechanical stimuli, and extracellular matrices that support more lifelike behavior and responsiveness. Moreover, automation and robotic handling systems are being introduced to streamline the culturing process, increasing throughput and reducing variability across batches. This scalability is essential for pharmaceutical companies that seek high-volume organoid models for preclinical drug screening and toxicology studies. Integration with high-content imaging and single-cell sequencing technologies is adding another layer of depth, allowing researchers to analyze organoid responses at a cellular and molecular level. Advances in gene editing tools such as CRISPR-Cas9 are also being used to introduce or correct mutations in iPSCs before organoid development, enabling the study of genetic diseases with unprecedented specificity. These ongoing innovations are not only improving the fidelity and functionality of organoids but also expanding their use across a growing number of scientific and clinical domains.

What Market and Research Needs Are Driving Broader Adoption of iPSC-Derived Organoids?

The demand for more accurate, human-relevant biological models is one of the primary forces driving the adoption of iPSC-derived organoids across pharmaceutical, academic, and clinical research sectors. Traditional two-dimensional cultures and animal models often fail to capture the complexity of human disease, leading to high attrition rates in drug development and limited translational outcomes. Organoids offer a solution to this challenge by providing systems that more closely reflect human physiology, thereby improving predictive accuracy for drug toxicity, metabolism, and therapeutic efficacy. This has become particularly important in oncology, where tumor-derived organoids are being used to screen compounds and personalize treatment strategies. Similarly, infectious disease researchers are turning to lung and intestinal organoids to study pathogen-host interactions in diseases such as COVID-19 and norovirus. The growing push for alternative testing models, driven by ethical concerns and regulatory pressure to reduce animal use, is also increasing reliance on organoid platforms. In the realm of regenerative medicine, iPSC-derived organoids offer a promising pathway for organ repair and transplantation, with experimental approaches showing potential for treating liver disease, retinal degeneration, and neurological disorders. Collaborations between biotechnology firms, universities, and healthcare institutions are accelerating both funding and innovation, making organoids more accessible to a broader range of researchers. These wide-ranging applications reflect an urgent and growing need for reliable, reproducible, and customizable models in the life sciences.

What Factors Are Fueling the Global Expansion of the iPSC-Derived Organoids Market?

The global market for iPSC-derived organoids is expanding rapidly due to a confluence of scientific, commercial, and policy-related drivers that are reshaping the landscape of biomedical research and therapeutic development. A major factor is the surge in demand for personalized medicine and precision diagnostics, both of which rely heavily on patient-specific models for treatment planning and drug testing. The increasing prevalence of chronic diseases and complex disorders has heightened the need for better tools to study disease mechanisms and evaluate therapeutic strategies. As a result, biotech companies and pharmaceutical giants are investing heavily in organoid technologies to improve early-stage drug screening and reduce late-stage clinical trial failures. Public and private funding for stem cell research is also on the rise, with government agencies and research foundations supporting initiatives that leverage iPSCs and organoids to accelerate innovation. Intellectual property surrounding organoid platforms is becoming more robust, encouraging commercial ventures to develop proprietary systems for organoid production, maintenance, and analysis. Furthermore, the emergence of dedicated organoid biobanks and standardized protocols is helping to overcome earlier challenges related to reproducibility and scalability. Academic institutions are incorporating organoid research into life sciences curricula, preparing the next generation of scientists to adopt and expand this technology. Global collaborations, open-access publications, and cross-border knowledge exchange are further enhancing accessibility and innovation. Together, these forces are not only sustaining the growth of the iPSC-derived organoid market but are also positioning it as a cornerstone of the future biomedical research ecosystem.

SCOPE OF STUDY:

The report analyzes the Induced Pluripotent Stem Cell (iPSC) Derived Organoids market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, Other Organoid Types); Application (Drug Discovery & Development Application, Disease Modelling Application, Regenerative Medicine Application); End-Use (Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use, Contract Research Organization End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 39 Featured) -

  • Axol Bioscience Ltd.
  • BICO Group AB
  • BioIVT
  • BioSpan Technologies, Inc.
  • BrainXell, Inc.
  • Censo Biotechnologies Ltd.
  • Cellular Dynamics International
  • DefiniGEN Ltd
  • Hubrecht Organoid Technology
  • I Peace, Inc.
  • InSphero AG
  • Kirkstall Ltd
  • MIMETAS B.V.
  • Molecular Devices, LLC
  • Ncardia AG
  • Novasenta Inc.
  • Organovo Holdings Inc.
  • REPROCELL Inc.
  • STEMCELL Technologies Inc.
  • Xilis, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Regenerative Medicine Throw the Spotlight on iPSC-Derived Organoids as Transformative Tools for Disease Modeling
    • Growing Focus on Personalized Medicine Propels Demand for Patient-Specific Organoids in Drug Screening and Therapeutic Testing
    • Here's the Story: iPSC Technology Enables Ethical, Scalable Alternatives to Embryonic Stem Cell-Derived Organoids
    • Expansion of 3D Cell Culture Platforms Strengthens the Business Case for Organoids in Translational and Preclinical Research
    • Rising Demand from Pharma and Biotech for Human-Relevant Models Drives Adoption in Toxicology and Efficacy Studies
    • Here's How Organoids Are Accelerating Innovation in Cancer Biology, Neurology, and Infectious Disease Research
    • Integration with CRISPR and Gene Editing Technologies Enhances Functional Validation and Target Discovery in Organoid Systems
    • Tissue-Specific Organoid Innovations Expand Applications in Gastrointestinal, Renal, Hepatic, and Pulmonary Disease Modeling
    • Here's How Organoid-on-a-Chip Systems Are Enabling Microphysiological Models for High-Throughput Screening
    • Growing Interest in Space Biology and Extreme Condition Testing Opens Niche Applications for Organoid Research
    • Artificial Intelligence and Automation Tools Create Opportunities for Scaling Organoid Analysis and Reproducibility
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Brain Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Brain Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Brain Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Heart Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Heart Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Heart Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lung Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lung Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Lung Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Liver Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Liver Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Liver Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Kidney Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Kidney Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Kidney Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Organoid Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Organoid Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Organoid Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Contract Research Organization End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Contract Research Organization End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Contract Research Organization End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Disease Modelling Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Disease Modelling Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Disease Modelling Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Regenerative Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • CHINA
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Induced Pluripotent Stem Cell (iPSC) Derived Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Type - Percentage Breakdown of Value Sales for Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids and Other Organoid Types for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organization End-Use for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of World 16-Year Perspective for Induced Pluripotent Stem Cell (iPSC) Derived Organoids by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Disease Modelling Application and Regenerative Medicine Application for the Years 2014, 2025 & 2030

IV. COMPETITION